Dubow Adam's Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Feb 18, 2026
- Accession no.
- 0001744507-26-000004
- Filed
- Feb 18, 2026
- Trade date
- Feb 15-17, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 5 derivative transactions. Open-market sales total $74.2K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dubow AdamCIK 0001744507 | Officer (Gen Counsel & Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +2,963 | – | – | 65,589 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +1,750 | – | – | 67,339 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +3,688 | – | – | 71,027 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +3,687 | – | – | 74,714 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +4,375 | – | – | 79,089 | Direct | |
| Feb 17, 2026 | Common Stock | SSaleDisposed | −6,395 | $11.60 | −$74,182 | 72,694 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −2,963 | $0.00 | $0 | 8,889 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −1,750 | $0.00 | $0 | 5,250 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −3,688 | $0.00 | $0 | 25,816 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −3,687 | $0.00 | $0 | 40,565 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −4,375 | $0.00 | $0 | 65,625 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.